Xie Qingqing, Sun Caixia, Fei Zhenghua, Yang Xujing
Department of Radiation and Medical Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People's Republic of China.
Department of Nursing, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People's Republic of China.
Patient Prefer Adherence. 2022 Jan 4;16:1-9. doi: 10.2147/PPA.S346171. eCollection 2022.
Tumor immunotherapy is a promising therapeutic strategy for patients with advanced cancers, and some tumors have profound and durable tumor regression. However, immunotherapy is still in the clinical trial stage with elusive long-term effects and complications as a new strategy. It is unclear whether patients possess an accurate understanding of the clinical benefits associated with these agents.
To investigate the anxiety and depression of patients with advanced cancer who received immunotherapy using programmed death-1 or programmed death-ligand 1 after multiline treatment failure, explore the influencing factors, and provide a reference for clinical medical staff and psychological support for patients.
The Hospital Anxiety and Depression Scale was used to calculate the anxiety and depression scores before and after 1, 2, and 3 courses of treatment, respectively. The patients with anxiety and depression were counted. Purposive sampling was used to conduct face-to-face semi-structured interviews with 21 patients to find out the reasons. The obtained data were analyzed and collated using Colaizzi's phenomenological method.
One hundred and twenty-six patients with advanced cancers were included in the study. Before and after 1, 2 and 3 courses of treatment, 18.26%, 23.0%, 50% and 54% of patients suffered from anxiety and depression, respectively. The proportion of patients with anxiety and depression during immunotherapy kept increasing, mainly due to therapeutic efficacy below expectation, lack of timely information after treatment, lack of awareness of treatment and drugs, and lack of family and social support.
Patients with advanced tumors after multiline treatment failure are susceptible to anxiety and depression during immunotherapy. It is necessary to test the emotional state of patients in time and carry out early intervention. Nursing staffs and medical staffs should adopt personalized measures to meet the psychological needs of patients.
肿瘤免疫疗法是晚期癌症患者一种很有前景的治疗策略,一些肿瘤可出现显著且持久的肿瘤消退。然而,作为一种新策略,免疫疗法仍处于临床试验阶段,其长期效果和并发症尚不明确。目前尚不清楚患者是否对这些药物的临床益处有准确的认识。
调查多线治疗失败后接受程序性死亡蛋白1或程序性死亡配体1免疫治疗的晚期癌症患者的焦虑和抑郁情况,探索其影响因素,为临床医护人员提供参考,并为患者提供心理支持。
分别采用医院焦虑抑郁量表计算1、2、3个疗程治疗前后的焦虑和抑郁评分。统计焦虑和抑郁患者人数。采用目的抽样法对21例患者进行面对面半结构式访谈以找出原因。运用Colaizzi现象学方法对所获数据进行分析整理。
本研究共纳入126例晚期癌症患者。在1、2、3个疗程治疗前后,分别有18.26%、23.0%、50%和54%的患者存在焦虑和抑郁。免疫治疗期间焦虑和抑郁患者的比例持续上升,主要原因是治疗效果未达预期、治疗后缺乏及时信息、对治疗和药物缺乏认识以及缺乏家庭和社会支持。
多线治疗失败后的晚期肿瘤患者在免疫治疗期间易出现焦虑和抑郁。有必要及时检测患者的情绪状态并进行早期干预。护理人员和医务人员应采取个性化措施满足患者的心理需求。